NCT00347555View on ClinicalTrials.gov

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Plasmodium Falciparum Malaria
Interventions
BIOLOGICAL

Aluminum Phosphate

1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.

DRUG

Placebo

0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).

BIOLOGICAL

EBA-175 RII-NG Malaria Vaccine

White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.

Trial Locations (1)

77030

Baylor College of Medicine - Molecular Virology and Microbiology, Houston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00347555 - Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly | Biotech Hunter | Biotech Hunter